Development of serine protease inhibitors displaying a multicentered short (<2.3 Å) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa

Journal of Medicinal Chemistry

Volumn 44, Issue 17, 2001, Pages 2753-2771

  Verner, E ^a   Katz, B A ^a   Spencer, J R ^a   Allen, D ^a   Hataye, J ^a   Hruzewicz, W ^a   Hui, H C ^a   Kolesnikov, A ^a   Li, Y ^a   Luong, C ^a   Martelli, A ^a   Radika, K ^a   Rai, R ^a   She, M ^a   Shrader, W ^a   Sprengeler, P A ^a   Trapp, S ^a   Wang, J ^a   Young, W B ^a   Mackman, R L ^a  

^a Axys Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 HYDROXYPHENYL) 1H BENZOIMIDAZOLE 5 CARBOXAMIDINE; BLOOD CLOTTING FACTOR 10A; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CATALYSIS; CELL INVASION; COVALENT BOND; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HYDROGEN BOND; NONHUMAN; PROTEIN DEGRADATION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

AMIDINES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FACTOR XA; HUMANS; HYDROGEN BONDING; INDOLES; MODELS, MOLECULAR; SERINE PROTEINASE INHIBITORS; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035899191     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0100638     Document Type: Article

References (42)

1. Design of potent selective zinc-mediated serine protease inhibitors
2. Inhibitors of serine proteinases
3. The urokinase-type plasminogen activator system in cancer metastasis: A review
4. Blood coagulation
5. Protease inhibitors: Current status and future prospects
6. Proteases and metastasis
7. Thrombin inhibitor design
8. Thrombosis and coagulation
9. Antithrombotics/serine proteases
10. Anticoagulants: Thrombin and factor Xa inhibitors
11. Emerging therapeutic targets in oncology: Urokinase-type plasminogen activator system
12. Inhibitors of Tryptase for the treatment of mast cell-mediated diseases
13. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group
14. New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue
15. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors
16. Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin
17. A novel approach to serine protease inhibition: Kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by zinc(II)
18. Oxyanion-mediated inhibition of serine proteases
19. A novel serine protease inhibition motif involving a multicentered short hydrogen bonding network at the active site
20. Development of potent and selective factor Xa inhibitors
21. Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases
22. Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles)
23. Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases
24. Synthesis and DNA interactions of benzimidazole dications which have activity against opportunistic infections
25. Synthetic utility of catalytic Fe(III)/Fe(II) redox cycling towards fused heterocycles: A facile access to substituted benzimidazole, bisbenzimidazole and imidazopyridine derivatives
26. Convenient method for the ortho-formylation of phenols
27. Derivatives of 5-amidine indole as inhibitors of thrombin catalytic activity
28. 1D]) receptor
29. The palladium-catalyzed cross-coupling reaction of phenylboronic acid with haloarenes in the presence of bases
30. An improved one-pot procedure for the synthesis of alkynes from aldehydes
31. A facile one-pot synthesis of polyfunctionalized 2-unsubstituted benzo[b]furans
32. High-throughput screening of enzyme inhibitors: Automatic determination of tight-binding inhibition constants
33. Structural basis for selectivity of a small molecule S1-binding submicromolar inhibitor of urokinase-type plasminogen activator
34. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite
35. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite
36. (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase
37. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors opens the way towards structure-based drug design